Gomisin N ameliorates autophagy-neuroinflammation imbalance in Parkinson's disease models via modulating the ATG16L1/NLRP3 axis.
GN is a brain-penetrant preclinical candidate that links ATG16L1-dependent autophagy with α-synuclein clearance and NLRP3 inflammasome suppression in PD models and completely abrogated the neuroprotective and anti-inflammatory effects of GN both in vitro and in vivo.